- Home
- INBX vs GNFT Comparison
INBX vs GNFT Comparison
Compare INBX & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- GNFT
- Stock Information
- Founded
- INBX 2010
- GNFT 1999
- Country
- INBX United States
- GNFT France
- Employees
- INBX N/A
- GNFT N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INBX Health Care
- GNFT Health Care
- Exchange
- INBX Nasdaq
- GNFT Nasdaq
- Market Cap
- INBX 178.5M
- GNFT 186.3M
- IPO Year
- INBX 2020
- GNFT 2019
- Fundamental
- Price
- INBX $21.60
- GNFT $3.80
- Analyst Decision
- INBX Hold
- GNFT Strong Buy
- Analyst Count
- INBX 1
- GNFT 1
- Target Price
- INBX N/A
- GNFT $13.00
- AVG Volume (30 Days)
- INBX 148.3K
- GNFT 3.0K
- Earning Date
- INBX 08-12-2025
- GNFT 09-18-2025
- Dividend Yield
- INBX N/A
- GNFT N/A
- EPS Growth
- INBX N/A
- GNFT N/A
- EPS
- INBX 111.58
- GNFT 0.03
- Revenue
- INBX $200,000.00
- GNFT $73,187,701.00
- Revenue This Year
- INBX N/A
- GNFT $5.15
- Revenue Next Year
- INBX N/A
- GNFT N/A
- P/E Ratio
- INBX $0.19
- GNFT $124.11
- Revenue Growth
- INBX N/A
- GNFT 105.01
- 52 Week Low
- INBX $10.80
- GNFT $2.55
- 52 Week High
- INBX $25.29
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- INBX 54.33
- GNFT 45.09
- Support Level
- INBX $20.84
- GNFT $3.94
- Resistance Level
- INBX $25.29
- GNFT $4.19
- Average True Range (ATR)
- INBX 1.84
- GNFT 0.11
- MACD
- INBX -0.41
- GNFT 0.01
- Stochastic Oscillator
- INBX 17.17
- GNFT 24.06
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.